Marc B. Garnick
Marc B. Garnick, M.D., is the Gorman Brothers Professor of Medicine at Harvard Medical School (HMS) and the Beth Israel Deaconess Medical Center, where he also directs the Hospital’s role as a tertiary cancer center for 7 affiliated community cancer centers. He completed his oncology training and faculty appointments in oncology at the Dana Farber Cancer Institute. He previously served as chief medical officer at Genetics Institute (sold to Wyeth Pharma) and executive vice president for clinical and regulatory development at Praecis Pharmaceuticals (sold to GSK). He serves as the editor in chief for The HMS Annual Report on Prostate Diseases, and its associated website. He served as the initial academic co-principal investigator for the commonly used prostate cancer drug leuprolide (Lupron) and was a member of the FDA/NCI consortium that led to initial approval of the drug cisplatin. He has just completed a 10 year tenure as a special governmental advisory member of multiple FDA panels and advisory committees. He currently serves on the boards (scientific and corporate) of several life science companies. He has served on the boards of trustees of the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine and is a trustee emeritus of Bowdoin College in Brunswick, Maine.